| |
Valid N
|
Total
|
|---|
|
Female Sex
|
245
|
145 (59.2%)
|
|
Mdn Age (IQR)
|
244
|
42.0 (35.0–50.5)
|
|
Mdn Months since HIV diagnosis (IQR)
|
205
|
0.82 (0.23–12.29)
|
|
Referred to KATH
|
189
|
92 (48.7%)
|
|
Constitutional Symptoms
|
240
|
65 (27.1%)
|
|
Neurological Symptoms
|
239
|
102 (42.7%)
|
|
Pulmonary Symptoms
|
240
|
81 (33.8%)
|
|
Cardiac symptoms
|
240
|
22 (9.2%)
|
|
Gastrointestinal Symptoms
|
241
|
58 (24.1%)
|
|
Other admission reason
|
243
|
15 (6.2%)
|
|
Known History of HIV
|
244
|
145 (59.4%)
|
|
HAART
|
237
|
99 (41.8%)
|
|
Clinical Stage
|
244
| |
|
Stage 0
| |
1 (0.4%)
|
|
Stage 1
| |
20 (8.2%)
|
|
Stage 2
| |
3 (1.2%)
|
|
Stage 3
| |
112 (45.9%)
|
|
Stage 4
| |
108 (44.3%)
|
|
Mdn Hemoglobin (IQR)
|
230
|
8.65 (6.90–10.90)
|
|
Mdn Platelet Count (IQR)
|
224
|
269.5 (149.0–377.0)
|
- Unless otherwise noted, valid counts are provided with column proportions. Mdn Median, IQR Interquartile range. HAART Highly active antiretroviral therapy, HIV Human immunodeficiency virus, KATH Komfo-Anokye Teaching Hospital
